The purpose of this fixed-dose combination is generally to provide symptomatic relief across key domains where discomfort or elevated temperature may involve symptoms that interfere with daily functioning or create noticeable physiological strain. It is relevant in clinical settings that involve acute or unstable symptom patterns and is applied in scenarios where short-term symptomatic assistance is appropriate.

---

Easing Acute and Episodic Pain Manifestations

This medication is commonly used to help with mild to moderate acute pain, and may assist with managing symptom intensity across a range of episodic or fluctuating manifestations. Key therapeutic applications may involve providing supportive relief for symptoms of increased neurological or muscular activity like headache (including tension-type and migraine), as well as managing localized acute pain such as toothache (odontalgia), muscular aches, and cyclical discomfort like primary dysmenorrhea. The supportive benefit contributes to improved comfort when symptoms intensify and create noticeable physiological strain.

Quick Fact: Symptomatic Support for Pain Commonly used for acute episodic pain including headache, toothache, and menstrual discomfort.

Mitigating Fever and Systemic Symptoms of Seasonal Illness

Citramon plus is applied across domains where additional symptomatic support is appropriate for the combined management of fever and associated systemic imbalance. This is particularly relevant in conditions characterized by periods of heightened symptoms of the common cold or influenza, where symptom clusters may be part of symptomatic management. By addressing both pain and fever, it provides support that helps ease the overall symptom burden, and may assist with maintaining a sense of stability during acute symptomatic episodes.

Regulatory References

1. NIH DailyMed overview

Eligibility Scope and Contraindications

Citramon plus (Acetaminophen, Aspirin, Caffeine) is officially labeled for use in Adults and Adolescents aged 12 years and older. However, regulatory documents establish explicit population eligibility constraints based on health status and age thresholds.

---

Absolute Prohibited Use (Contraindications)

Use is prohibited for patients with a known severe allergy or hypersensitivity to Acetaminophen, Aspirin (or other salicylates), Caffeine, or any NSAID. The medication is strictly contraindicated for patients with severe active liver disease or peptic ulcers. Patients must not take this if they are also using any other medicine containing Acetaminophen or Aspirin. The drug is absolutely contraindicated during the third trimester of pregnancy (from 20 weeks onward).

---

Conditional or Restricted Use

Specific populations are designated for conditional use and must ask a health professional before use. These include adults aged 60 or older and individuals with pre-existing conditions such as kidney disease, heart disease, high blood pressure, asthma, or any history of bleeding problems. Use is also restricted for children and teenagers recovering from chickenpox or flu-like symptoms due to the associated risk of Reye's syndrome. Use during breastfeeding is conditional and requires professional consultation.

Interactions with other medicines and products

This combination product contains aspirin, acetaminophen, and caffeine, resulting in a broad interaction profile that requires caution when used with other medications.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is restricted due to the caffeine component. Use with any other product containing acetaminophen is strictly prohibited to avoid the cumulative risk of severe liver damage. Concomitant use with alcohol is also restricted due to increased risk of hepatotoxicity and gastrointestinal bleeding.

Clinically Significant Interactions

Product Category	Interaction Implication
Oral Anticoagulants (e.g., Warfarin)	Increased risk of bleeding due to the aspirin component. Requires close monitoring.
Other NSAIDs/Aspirin Products	Increased risk of gastrointestinal bleeding and ulceration. Combination should be avoided.
Enzyme Inhibitors (e.g., Cimetidine, Ketoconazole)	May decrease the clearance of the product's components, potentially leading to increased concentrations.
Uricosuric Agents (e.g., Probenecid)	The aspirin component may counteract the effect of the uricosuric agent, reducing its therapeutic benefit.
Methotrexate	May interfere with Methotrexate clearance, potentially leading to toxic concentrations.
Mifepristone	Co-administration is restricted for several days following Mifepristone administration.

Patients should limit the intake of other caffeine sources (e.g., coffee, tea, soft drinks) to avoid excessive caffeine exposure.

How Citramon plus Works: Pharmacodynamic Mechanism

Citramon plus exerts its influence through a multi-target pharmacodynamic mechanism involving three active components.

Modulating Eicosanoid Pathways

Acetylsalicylic Acid (ASA) and Paracetamol primarily affect the body's synthesis of prostaglandins—lipid mediators that influence nociception, inflammatory processes, and thermoregulation. ASA achieves this via the irreversible inhibition of Cyclooxygenase (COX) enzymes. Paracetamol contributes through the modulation of COX activity, particularly within the Central Nervous System (CNS). This process reduces the availability of sensitizing mediators, leading to the modulation of nociceptive signaling and thermoregulatory processes.

Central Modulation and Synergy

Caffeine acts as a non-selective adenosine receptor antagonist (primarily A1 and A2A) in the CNS, blocking the inhibitory effects of adenosine on neuronal activity. Paracetamol also modulates descending serotonergic pain pathways, influencing nociceptive input integration. The combined central and peripheral action, where Caffeine contributes to the potentiation of ASA and Paracetamol's effects, represents a pharmacodynamic synergy. This integrated influence targets multiple physiological systems, including nociception and arousal levels.

The administration of the Acetaminophen/Acetylsalicylic Acid/Caffeine fixed-dose combination, often referred to as Citramon plus, is governed by standardized protocols. This section describes the high-level administration guidelines without addressing efficacy or safety.

---

Administration Scope

Parameter	Standardized Instructions
Route of administration	Oral: The medication is intended for ingestion as a tablet, caplet, or similar solid form.
Dosing schedule	Unit Dose: Two tablets. Maximum Daily Dose: Not to exceed eight tablets in 24 hours.
Frequency	Dosing is typically repeated every four to six hours, maintaining the minimum required time interval between administrations.
Age-group rules	Authorized for use in individuals 12 years of age and older, following the standard adult dosing regimen.
Special procedural conditions	Each dose must be taken with a full glass of water. Use is limited to temporary relief, generally not exceeding 10 days for pain or 3 days for fever.

---

Procedural Structure and Constraints

The use protocol establishes a standardized oral, intermittent regimen for the short-term administration of this fixed-dose combination. The procedural structure begins with a fixed two-tablet unit dose and requires strict adherence to the four-to-six-hour interval, ensuring the overall exposure does not exceed the maximum daily limit. A core administration constraint mandates the avoidance of any other medication containing acetaminophen while using this product. This structured approach defines the required parameters for use.

The research base for this combination of Acetaminophen, Acetylsalicylic Acid, and Caffeine primarily consists of Randomized Controlled Trials (RCTs) and meta-analyses that have evaluated its role in conditions characterized by episodic headache manifestations, such as migraine and tension-type headaches. These acute, large-scale studies prioritized the measurement of pain-free status at the 2-hour measurement point and tracked changes in the ability to return to usual daily activities. Findings describe patterns observed in these studies compared to placebo controls.

Research has also explored the combination's role in conditions involving acute or episodic symptoms, including toothache, muscular aches, and fever. For these uses, studies monitored total symptom change measured over time and changes in body’s temperature. Evidence for some minor acute pain uses is limited and often relies on extrapolation from the known efficacy of the individual components, meaning the evidence quality varies across these different acute contexts.

The research is concentrated on short-term, single-dose administration, meaning follow-up durations were strictly limited to a few hours. Consequently, long-term effects are not fully established, and there is limited information regarding outcomes over extended time periods. Furthermore, specific data for certain groups, such as older adults or individuals with pre-existing comorbid conditions, remain insufficient, and the results apply only to the general adult populations studied.

Key Studies & References

1. Acetaminophen/Aspirin/Caffeine - StatPearls - NCBI Bookshelf - NIH.
2. Label: ACETAMINOPHEN, ASPIRIN, CAFFEINE tablet, film coated - DailyMed - NIH.

Common questions about Citramon plus (FAQ)

Q: What is Citramon plus actually used to treat?

According to official product information, this medicine is indicated for the temporary relief of pain associated with conditions such as headache, muscle aches, and toothache. It is also officially indicated for use in reducing fever.

Q: What are the main active ingredients in Citramon plus?

This product is a fixed-dose combination medicine. The active ingredients listed in regulatory documents are Acetaminophen, Aspirin (Acetylsalicylic Acid), and Caffeine.

Q: How does Citramon plus differ from a standard pain reliever like aspirin alone?

Official documents describe this product as a combination medicine. The addition of Acetaminophen and Caffeine is noted to contribute to the overall effect, which differs from taking a single pain-relieving component alone.

Q: Is Citramon plus generally available over-the-counter or only by prescription?

The availability of this medicine (whether it requires a prescription or is non-prescription) is determined by the local regulatory requirements for its authorized dose. Availability status can vary by country.

Q: Does Citramon plus interact with common blood pressure medications?

Regulatory documents list interactions with certain medicines, including some that may be used to treat high blood pressure. Official documentation notes that caution is required regarding co-administration with other substances.

Q: How long does it typically take for Citramon plus to start working?

Clinical study data, often summarized in product information, indicates that the onset of the medicine's pain-relieving effect typically begins within 15 to 30 minutes after administration.

Q: What is the expected duration of effect after taking Citramon plus?

The documented duration of pain relief following a unit dose is generally described in official product information as lasting approximately four to six hours.

Q: Are there specific pre-existing medical conditions that restrict the use of Citramon plus?

Official labeling states that the medicine is contraindicated in patients with severe liver or kidney failure, and in those with a known allergy to any active ingredient or NSAIDs (non-steroidal anti-inflammatory drugs).

Q: Does Citramon plus have any documented interactions with herbal supplements?

The labeling advises caution and a full review when co-administering the medicine with other substances, including herbal supplements. This is due to the potential for interaction risks with the active components.

Q: What does official guidance suggest regarding taking Citramon plus with food?

Official guidance permits use with food or milk to help minimize potential stomach upset. The label specifies that the dose must be taken with a full glass of water.

Q: Is the onset of action of Citramon plus documented in the drug's patient information leaflet?

Yes, regulatory authorities require that information regarding the medicine's typical onset of action is included. This data is generally present in the patient information leaflet or consumer medical information provided with the product.

Q: How is Citramon plus classified by regulatory bodies (e.g., narcotic, scheduled drug)?

According to international drug scheduling regulations, this product is generally not classified as a narcotic or controlled substance.

Q: What does official information say about what to do after a person misses a dose?

Official information regarding a missed dose states that the subsequent dose should be taken only after the required time interval has passed. The guidance also cautions against taking a double dose.

Q: Do official documents address the potential for 'rebound headaches' with Citramon plus?

Regulatory documents include a warning that overuse of the medicine can lead to a condition known as 'medication-overuse headache' (MOH). This condition is also sometimes referred to as a 'rebound headache'.

Q: What is the process for reporting a side effect related to Citramon plus?

The official drug documentation provides information on how adverse reactions can be reported to the national drug regulatory body (e.g., FDA or EMA).

Q: Does the medicine come with a specific patient information guide?

Regulatory requirements mandate that a Patient Information Leaflet or Consumer Medical Information (CMI) must be dispensed with the medicine. This guide provides detailed information on use, safety, and warnings.

Q: What does official information say about Citramon plus during breastfeeding?

Official labeling notes that the decision regarding use during breastfeeding requires consideration of the importance of the drug to the mother and the potential risks to the infant.

Q: How is the safety of Citramon plus monitored after it is released to the public?

The safety of the medicine is subject to post-marketing surveillance. This means regulatory authorities continuously perform monitoring to track and evaluate the medicine's safety profile over time.

Q: What types of pain is Citramon plus typically used for according to official documents?

The medicine is officially indicated for the temporary relief of pain associated with conditions such as headache, muscle aches, and toothache. It is also officially indicated for use in reducing fever.

Q: Does Citramon plus have a documented effect on inflammation?

One of the active components, Acetylsalicylic Acid (Aspirin), is known to influence inflammatory processes by inhibiting prostaglandin synthesis. However, the overall product is not primarily indicated as an anti-inflammatory drug.

Q: What signs should a person watch for when first taking Citramon plus?

Official documents highlight the serious risk of gastrointestinal bleeding and acute liver failure associated with the components. Official documents state that immediate medical attention should be sought if signs of these severe reactions are observed.

Q: Are there any specific foods or drinks that should be avoided when taking Citramon plus?

Official guidance states that the medicine is restricted for use with alcohol. Furthermore, the label notes that the intake of other products containing caffeine should be limited.

Q: What are the general guidelines for use in elderly patients?

Official labeling notes that older adults (age 60 and over) have an increased risk of severe gastrointestinal bleeding when using the medicine. This increased risk is a key consideration for use in this population.

Q: Who is generally advised not to use Citramon plus based on official warnings?

The medicine is contraindicated for use in individuals under 12, those in the last trimester of pregnancy, and patients with known hypersensitivity. It is also prohibited for use by anyone taking other acetaminophen-containing products.

Q: Where can I find published clinical evidence for Citramon plus?

Regulatory bodies make information about clinical trials, including summaries of the evidence, publicly accessible through their specific drug information databases. These databases provide authorized details regarding the studies that support the drug's use.

Q: Are there different formulations of Citramon plus available, such as liquid or chewable?

Regulatory documentation describes the authorized forms for this product as tablets or caplets. These are solid oral dosage forms intended for ingestion.

Q: Why might a person feel jittery or restless after taking Citramon plus?

The medicine contains caffeine, which is known to act as a stimulant on the central nervous system. Official documents list nervousness and insomnia as common adverse reactions potentially related to this component.

Q: Is Citramon plus described for use in people with liver or kidney concerns?

Official labeling strictly contraindicates use in patients with severe liver failure. The label also specifies that caution is required for individuals with chronic kidney disease.

Q: Are there any known issues with taking Citramon plus before driving or operating machinery?

Official labeling warns that the medicine may cause adverse reactions such as dizziness or drowsiness. These effects could potentially impair a person's ability to drive a vehicle or safely operate machinery.

Storage and Disposal Instructions for Citramon Plus

Citramon Plus must be stored at controlled room temperature, maintaining a required range of 20 C to 25 C (68 F to 77 F). The container must be kept closed tightly to protect the contents from moisture, and the storage environment should be dry and well-ventilated.

Required Conditions

Condition	Requirement
Temperature	20 C to 25 C (68 F to 77 F)
Protection	Keep container tightly closed; store in a dry place
Child Safety	Must be kept out of reach of children

Disposal of unused or expired medicine must follow local guidelines. Do not dispose of the product in household trash or wastewater unless specifically advised by a local drug take-back program or pharmaceutical waste authority.